Fig. 3From: Data quality considerations for evaluating COVID-19 treatments using real world data: learnings from the National COVID Cohort Collaborative (N3C)Distribution of remdesivir treatment durations for (a) all treated patients and (b) patients whose treatment did not terminate with discharge or deathBack to article page